Clinical Trial Update: CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus [Phase 3]

View source ↗

Summary

Phase 3 trial update for CR845 in hemodialysis patients with uremic pruritus has completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uremic Pruritus

Drugs mentioned

• CR845 (difelikefalin)

Snippet

Sponsor: Cara Therapeutics, Inc. | Conditions: Uremic Pruritus | Phase 3 | Status: COMPLETED | Results posted: 2022-04-26